Graham Mazereeuw

1.0k total citations
17 papers, 765 citations indexed

About

Graham Mazereeuw is a scholar working on Cardiology and Cardiovascular Medicine, Nutrition and Dietetics and Biological Psychiatry. According to data from OpenAlex, Graham Mazereeuw has authored 17 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 6 papers in Nutrition and Dietetics and 5 papers in Biological Psychiatry. Recurrent topics in Graham Mazereeuw's work include Tryptophan and brain disorders (5 papers), Cardiac Health and Mental Health (5 papers) and Fatty Acid Research and Health (4 papers). Graham Mazereeuw is often cited by papers focused on Tryptophan and brain disorders (5 papers), Cardiac Health and Mental Health (5 papers) and Fatty Acid Research and Health (4 papers). Graham Mazereeuw collaborates with scholars based in Canada, United States and United Kingdom. Graham Mazereeuw's co-authors include Krista L. Lanctôt, Nathan Herrmann, Walter Swardfager, Sarah Chau, Paul Oh, David N. Juurlink, David W.L., Roger S. McIntyre, S. Danielle and Mark D. Sullivan and has published in prestigious journals such as Biological Psychiatry, Pain and Neuroscience & Biobehavioral Reviews.

In The Last Decade

Graham Mazereeuw

17 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Graham Mazereeuw Canada 12 273 208 163 112 94 17 765
Ziva Stahl Israel 7 231 0.8× 213 1.0× 85 0.5× 85 0.8× 148 1.6× 11 730
Andrzej Pająk Poland 12 213 0.8× 305 1.5× 380 2.3× 66 0.6× 151 1.6× 22 1.3k
Annalisa Opizzi Italy 21 366 1.3× 425 2.0× 181 1.1× 58 0.5× 86 0.9× 36 1.1k
Miho Itomura Japan 15 617 2.3× 247 1.2× 125 0.8× 34 0.3× 86 0.9× 29 945
Chieh‐Liang Huang Taiwan 15 160 0.6× 168 0.8× 139 0.9× 215 1.9× 351 3.7× 36 1.2k
Hüseyin Avni Uydu Türkiye 14 110 0.4× 154 0.7× 95 0.6× 341 3.0× 88 0.9× 42 1.2k
Daisy Zamora United States 19 719 2.6× 533 2.6× 435 2.7× 85 0.8× 168 1.8× 43 1.6k
Janet Shay United Kingdom 8 308 1.1× 235 1.1× 75 0.5× 85 0.8× 55 0.6× 8 621
Babak Hooshmand Sweden 15 98 0.4× 320 1.5× 153 0.9× 43 0.4× 248 2.6× 30 990
Shigeki Sawazaki Japan 19 678 2.5× 225 1.1× 128 0.8× 23 0.2× 88 0.9× 33 1.0k

Countries citing papers authored by Graham Mazereeuw

Since Specialization
Citations

This map shows the geographic impact of Graham Mazereeuw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graham Mazereeuw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graham Mazereeuw more than expected).

Fields of papers citing papers by Graham Mazereeuw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Graham Mazereeuw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graham Mazereeuw. The network helps show where Graham Mazereeuw may publish in the future.

Co-authorship network of co-authors of Graham Mazereeuw

This figure shows the co-authorship network connecting the top 25 collaborators of Graham Mazereeuw. A scholar is included among the top collaborators of Graham Mazereeuw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graham Mazereeuw. Graham Mazereeuw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mazereeuw, Graham, Tara Gomes, Erin M. Macdonald, et al.. (2020). Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Case–Control Study. Drug Safety. 43(8). 737–743. 4 indexed citations
2.
Saleem, Mahwesh, Nathan Herrmann, Adam Dinoff, et al.. (2018). Association Between Endothelial Function and Cognitive Performance in Patients With Coronary Artery Disease During Cardiac Rehabilitation. Psychosomatic Medicine. 81(2). 184–191. 19 indexed citations
3.
Mazereeuw, Graham, Mark D. Sullivan, & David N. Juurlink. (2018). Depression in chronic pain: might opioids be responsible?. Pain. 159(11). 2142–2145. 27 indexed citations
4.
Suridjan, Ivonne, Dana Mohammad, Nathan Herrmann, et al.. (2018). Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease. Journal of the American Heart Association. 7(10). 12 indexed citations
5.
Mazereeuw, Graham, Nathan Herrmann, Ana C. Andreazza, et al.. (2017). Baseline Oxidative Stress Is Associated with Memory Changes in Omega-3 Fatty Acid Treated Coronary Artery Disease Patients. PubMed. 2017. 1–7. 8 indexed citations
6.
Cressman, Alex, et al.. (2017). Availability of naloxone in Canadian pharmacies:a population-based survey. CMAJ Open. 5(4). E779–E784. 21 indexed citations
7.
Mazereeuw, Graham, Nathan Herrmann, Ana C. Andreazza, et al.. (2016). Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain Behavior and Immunity. 60. 136–141. 27 indexed citations
8.
Mazereeuw, Graham, Nathan Herrmann, Paul Oh, et al.. (2016). Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease. Journal of Clinical Psychopharmacology. 36(5). 436–444. 37 indexed citations
9.
Lanctôt, Krista L., et al.. (2015). Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer’s Disease. The Journal of Clinical Psychiatry. 76(11). e1424–e1431. 42 indexed citations
10.
Mazereeuw, Graham, Nathan Herrmann, David W.L., et al.. (2015). Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. Brain Behavior and Immunity. 53. 54–58. 8 indexed citations
11.
Lanctôt, Krista L., et al.. (2014). The Platelet Activating Factor PC(O-18:3/2:0) is Associated with Apathy Independently of Depressive Symptoms in Depressed Patients with Coronary Artery Disease. American Journal of Geriatric Psychiatry. 22(3). S110–S110. 1 indexed citations
12.
Mazereeuw, Graham, Nathan Herrmann, Daniel Figeys, et al.. (2014). Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. Journal of Neuroinflammation. 11(1). 119–119. 8 indexed citations
13.
Swardfager, Walter, Nathan Herrmann, Roger S. McIntyre, et al.. (2013). Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neuroscience & Biobehavioral Reviews. 37(5). 911–929. 92 indexed citations
14.
Swardfager, Walter, et al.. (2013). Zinc in Depression: A Meta-Analysis. Biological Psychiatry. 74(12). 872–878. 180 indexed citations
15.
Mazereeuw, Graham, Nathan Herrmann, Steffany A. L. Bennett, et al.. (2013). Platelet activating factors in depression and coronary artery disease: A potential biomarker related to inflammatory mechanisms and neurodegeneration. Neuroscience & Biobehavioral Reviews. 37(8). 1611–1621. 37 indexed citations
16.
Mazereeuw, Graham, Krista L. Lanctôt, Sarah Chau, Walter Swardfager, & Nathan Herrmann. (2012). Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiology of Aging. 33(7). 1482.e17–1482.e29. 183 indexed citations
17.
Swardfager, Walter, Nathan Herrmann, Stephen M. Cornish, et al.. (2012). Exercise intervention and inflammatory markers in coronary artery disease: A meta-analysis. American Heart Journal. 163(4). 666–676.e3. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ziva Stahl Breakdown of academic impact, for papers by Andrzej Pająk Breakdown of academic impact, for papers by Annalisa Opizzi Breakdown of academic impact, for papers by Miho Itomura Breakdown of academic impact, for papers by Chieh‐Liang Huang Breakdown of academic impact, for papers by Hüseyin Avni Uydu Breakdown of academic impact, for papers by Daisy Zamora Breakdown of academic impact, for papers by Janet Shay Breakdown of academic impact, for papers by Babak Hooshmand Breakdown of academic impact, for papers by Shigeki Sawazaki
Rankless by CCL
2026